1
|
Wang H, Zhang X, Kang P, Cui X, Hao G, Wang Z, Han B, Lv X, Zhang J, Ge W. Variations in Oligosaccharides and N/ O-Glycans in Human Milk through the Eight-Month Lactation Period. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2022; 70:14272-14283. [PMID: 36315615 DOI: 10.1021/acs.jafc.2c05869] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Oligosaccharides and N/O-glycans are abundant in human milk and have numerous biological functions (for instance sialylated glycans provide sialic acid for the growth of infant brains), but their variation trends during lactation need further exploration. Qualitative and quantitative analyses of oligosaccharides and N/O-glycans in human milk at different lactation stages (from 7 days to 8 months) were performed using UHPLC-ESI-MS/MS. Thirty-four oligosaccharides, twenty-three N-glycans, and six O-glycans were identified. Oligosaccharides showed the highest abundance in human colostrum and decreased with the progression of lactation, and the abundance of N/O-glycans fluctuated as lactation progressed, while a high abundance of sialylated oligosaccharides and sialylated N/O-glycans was observed in human colostrum. These findings provide evidence for breastfeeding support and contribute to the development of infant formula supplemented with human milk glycans.
Collapse
Affiliation(s)
- Haiyan Wang
- College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China
| | - Ximei Zhang
- College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China
| | - Peng Kang
- College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China
| | - Xiuxiu Cui
- Xi'an Baiyue Goat Dairy Group Co., Ltd, Yanliang 710089, China
| | - Guo Hao
- Shaanxi Goat Milk Product Quality Supervision and Inspection Center, Fuping 711700, China
| | - Zhongfu Wang
- The College of Life Sciences, Northwest University, Xi'an 710069, China
| | - Bei Han
- School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an 710000, China
| | - Xin Lv
- College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China
| | - Jing Zhang
- College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China
| | - Wupeng Ge
- College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China
| |
Collapse
|
2
|
Kołaczkowski BM, Jørgensen CI, Spodsberg N, Stringer MA, Supekar NT, Azadi P, Westh P, Krogh KBRM, Jensen K. Analysis of fungal high-mannose structures using CAZymes. Glycobiology 2021; 32:304-313. [PMID: 34939126 PMCID: PMC8970417 DOI: 10.1093/glycob/cwab127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 12/01/2021] [Accepted: 12/02/2021] [Indexed: 12/24/2022] Open
Abstract
Glycoengineering ultimately allows control over glycosylation patterns to generate new glycoprotein variants with desired properties. A common challenge is glycan heterogeneity, which may affect protein function and limit the use of key techniques such as mass spectrometry. Moreover, heterologous protein expression can introduce nonnative glycan chains that may not fulfill the requirement for therapeutic proteins. One strategy to address these challenges is partial trimming or complete removal of glycan chains, which can be obtained through selective application of exoglycosidases. Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase. The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A). Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A. This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
Collapse
Affiliation(s)
- Bartłomiej M Kołaczkowski
- Department of Science and Environment, Roskilde University, Universitetsvej 1, Building 28, Roskilde 4000, Denmark
| | | | | | - Mary A Stringer
- Novozymes A/S, Biologiens Vej 2, Kongens Lyngby 2800, Denmark
| | - Nitin T Supekar
- Complex Carbohydrate Research Center, 315 Riverbend Rd. University of Georgia, Athens, Georgia 30602 USA
| | - Parastoo Azadi
- Complex Carbohydrate Research Center, 315 Riverbend Rd. University of Georgia, Athens, Georgia 30602 USA
| | - Peter Westh
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Building 224, Kongens Lyngby 2800, Denmark
| | | | - Kenneth Jensen
- To whom correspondence should be addressed: Tel: +45-307-70529; e-mail:
| |
Collapse
|
3
|
Radoman B, Grünwald-Gruber C, Schmelzer B, Zavec D, Gasser B, Altmann F, Mattanovich D. The Degree and Length of O-Glycosylation of Recombinant Proteins Produced in Pichia pastoris Depends on the Nature of the Protein and the Process Type. Biotechnol J 2020; 16:e2000266. [PMID: 32975831 DOI: 10.1002/biot.202000266] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 09/09/2020] [Indexed: 12/16/2022]
Abstract
The methylotrophic yeast Pichia pastoris is known as an efficient host for the production of heterologous proteins. While N-linked protein glycosylation is well characterized in P. pastoris there is less knowledge of the patterns of O-glycosylation. O-glycans produced by P. pastoris consist of short linear mannose chains, which in the case of recombinant biopharmaceuticals can trigger an immune response in humans. This study aims to reveal the influence of different cultivation strategies on O-mannosylation profiles in P. pastoris. Sixteen different model proteins, produced by different P. pastoris strains, are analyzed for their O-glycosylation profile. Based on the obtained data, human serum albumin (HSA) is chosen to be produced in fast and slow growth fed batch fermentations by using common promoters, PGAP and PAOX1 . After purification and protein digestion, glycopeptides are analyzed by LC/ESI-MS. In the samples expressed with PGAP it is found that the degree of glycosylation is slightly higher when a slow growth rate is used, regardless of the efficiency of the producing strain. The highest glycosylation intensity is observed in HSA produced with PAOX1 . The results indicate that the O-glycosylation level is markedly higher when the protein is produced in a methanol-based expression system.
Collapse
Affiliation(s)
- Bojana Radoman
- Austrian Centre of Industrial Biotechnology (ACIB), Vienna, 1190, Austria.,Department of Biotechnology, BOKU-University of Natural Resources and Life Sciences, Vienna, 1190, Austria
| | - Clemens Grünwald-Gruber
- Department of Chemistry, BOKU-University of Natural Resources and Life Sciences, Vienna, 1190, Austria
| | - Bernhard Schmelzer
- Austrian Centre of Industrial Biotechnology (ACIB), Vienna, 1190, Austria.,Department of Biotechnology, BOKU-University of Natural Resources and Life Sciences, Vienna, 1190, Austria
| | - Domen Zavec
- Department of Biotechnology, BOKU-University of Natural Resources and Life Sciences, Vienna, 1190, Austria
| | - Brigitte Gasser
- Austrian Centre of Industrial Biotechnology (ACIB), Vienna, 1190, Austria.,Department of Biotechnology, BOKU-University of Natural Resources and Life Sciences, Vienna, 1190, Austria
| | - Friedrich Altmann
- Austrian Centre of Industrial Biotechnology (ACIB), Vienna, 1190, Austria.,Department of Chemistry, BOKU-University of Natural Resources and Life Sciences, Vienna, 1190, Austria
| | - Diethard Mattanovich
- Austrian Centre of Industrial Biotechnology (ACIB), Vienna, 1190, Austria.,Department of Biotechnology, BOKU-University of Natural Resources and Life Sciences, Vienna, 1190, Austria
| |
Collapse
|
4
|
Li S, Sun P, Gong X, Chang S, Li E, Xu Y, Wu J, Liu B. Engineering O-glycosylation in modified N-linked oligosaccharide (Man 12GlcNAc 2∼Man 16GlcNAc 2) Pichia pastoris strains. RSC Adv 2019; 9:8246-8252. [PMID: 35518704 PMCID: PMC9061240 DOI: 10.1039/c8ra08121b] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Accepted: 02/19/2019] [Indexed: 11/24/2022] Open
Abstract
Yeast have been engineered for the production of therapeutic glycoproteins with humanized N-linked oligosaccharides. Both N- and O-linked oligosaccharides engineered yeast have been attractive prospects, since yeast-specific O-mannosylated proteins were reported to induce an aberrant immune response and alter pharmacokinetics in vivo. In the present study, we genetically manipulated O-glycosylation by disrupting O-mannosyltransferase PMT1 and PMT5 in a low-mannose type N-linked oligosaccharide (Man12GlcNAc2∼Man16GlcNAc2) engineered Pichia pastoris strain to produce therapeutic glycoproteins. The O-mannosyltransferase PMT1 mutant produces anti-Her-2 antibodies with reduced O-linked oligosaccharides and protein degradation, but this strain exhibited growth defects. However, the deletion of O-mannosyltransferase PMT5 individually has a minimal effect on O-glycosylation, degradation of the anti-Her-2 antibody, and strain growth. Thus, by disrupting O-mannosyltransferase PMT1 in an N-glycosylation engineered Pichia pastoris strain, we generated an effective glycoengineered Pichia pastoris strain to effectively produce therapeutic glycoproteins with both engineered N- and O-linked oligosaccharides.
Collapse
Affiliation(s)
- Siqiang Li
- Beijing Institute of Biotechnology Beijing 100071 China +861063833521
- School of Biological and Food Engineering, Huanghuai University Zhumadian 463000 China
| | - Peng Sun
- Beijing Institute of Biotechnology Beijing 100071 China +861063833521
| | - Xin Gong
- Beijing Institute of Biotechnology Beijing 100071 China +861063833521
| | - Shaohong Chang
- Beijing Institute of Biotechnology Beijing 100071 China +861063833521
| | - Enzhong Li
- School of Biological and Food Engineering, Huanghuai University Zhumadian 463000 China
| | - Yuanhong Xu
- School of Biological and Food Engineering, Huanghuai University Zhumadian 463000 China
| | - Jun Wu
- Beijing Institute of Biotechnology Beijing 100071 China +861063833521
| | - Bo Liu
- Beijing Institute of Biotechnology Beijing 100071 China +861063833521
| |
Collapse
|
5
|
Granger BL. Accessibility and contribution to glucan masking of natural and genetically tagged versions of yeast wall protein 1 of Candida albicans. PLoS One 2018; 13:e0191194. [PMID: 29329339 PMCID: PMC5766240 DOI: 10.1371/journal.pone.0191194] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Accepted: 12/30/2017] [Indexed: 02/06/2023] Open
Abstract
Yeast wall protein 1 (Ywp1) is an abundant glycoprotein of the cell wall of the yeast form of Candida albicans, the most prevalent fungal pathogen of humans. Antibodies that bind to the polypeptide backbone of isolated Ywp1 show little binding to intact yeast cells, presumably because the Ywp1 epitopes are masked by the polysaccharides of the mannoproteins that form the outer layer of the cell wall. Rare cells do exhibit much greater anti-Ywp1 binding, however, and one of these was isolated and characterized. No differences were seen in its Ywp1, but it exhibited greater adhesiveness, sensitivity to wall perturbing agents, and exposure of its underlying β-1,3-glucan layer to external antibodies. The molecular basis for this greater epitope accessibility has not been determined, but has facilitated exploration of how these properties change as a function of cell growth and morphology. In addition, previously engineered strains with reduced quantities of Ywp1 in their cell walls were also found to have greater β-1,3-glucan exposure, indicating that Ywp1 itself contributes to the masking of wall epitopes, which may be important for understanding the anti-adhesive effect of Ywp1. Ectopic production of Ywp1 by hyphae, which reduces the adhesivity of these filamentous forms of C. albicans, was similarly found to reduce exposure of the β-1,3-glucan in their walls. To monitor Ywp1 in the cell wall irrespective of its accessibility, green fluorescent protein (Gfp) was genetically inserted into wall-anchored Ywp1 using a bifunctional cassette that also allowed production from a single transfection of a soluble, anchor-free version. The wall-anchored Ywp1-Gfp-Ywp1 accumulated in the wall of the yeast forms but not hyphae, and appeared to have properties similar to native Ywp1, including its adhesion-inhibiting effect. Some pseudohyphal walls also detectably accumulated this probe. Strains of C. albicans with tandem hemagglutinin (HA) epitopes inserted into wall-anchored Ywp1 were previously created by others, and were further explored here. As above, rare cells with much greater accessibility of the HA epitopes were isolated, and also found to exhibit greater exposure of Ywp1 and β-1,3-glucan. The placement of the HA cassette inhibited the normal N-glycosylation and propeptide cleavage of Ywp1, but the wall-anchored Ywp1-HA-Ywp1 still accumulated in the cell wall of yeast forms. Bifunctional transformation cassettes were used to additionally tag these molecules with Gfp, generating soluble Ywp1-HA-Gfp and wall-anchored Ywp1-HA-Gfp-Ywp1 molecules. The former revealed unexpected electrophoretic properties caused by the HA insertion, while the latter further highlighted differences between the presence of a tagged Ywp1 molecule (as revealed by Gfp fluorescence) and its accessibility in the cell wall to externally applied antibodies specific for HA, Gfp and Ywp1, with accessibility being greatest in the rapidly expanding walls of budding daughter cells. These strains and results increase our understanding of cell wall properties and how C. albicans masks itself from recognition by the human immune system.
Collapse
Affiliation(s)
- Bruce L. Granger
- Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, United States of America
- * E-mail:
| |
Collapse
|
6
|
Engineering of Yeast Glycoprotein Expression. ADVANCES IN BIOCHEMICAL ENGINEERING/BIOTECHNOLOGY 2018; 175:93-135. [DOI: 10.1007/10_2018_69] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
7
|
Abe H, Tomimoto K, Fujita Y, Iwaki T, Chiba Y, Nakayama KI, Nakajima Y. Development of N- and O-linked oligosaccharide engineered Saccharomyces cerevisiae strain. Glycobiology 2016; 26:1248-1256. [PMID: 27496768 DOI: 10.1093/glycob/cww071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Revised: 06/29/2016] [Accepted: 07/05/2016] [Indexed: 11/14/2022] Open
Abstract
Yeast cells have been engineered for the production of glycoproteins as biopharmaceuticals with humanized N-linked oligosaccharides. The suppression of yeast-specific O-mannosylation is important to reduce immune response and to improve heterologous protein productivity in the production of biopharmaceuticals. However, so far, there are few reports of the engineering of both N-linked and O-linked oligosaccharides in yeast cells. In the present study, we describe the generation of a Saccharomyces cerevisiae strain capable of producing a glycoprotein with humanized Man5GlcNAc2 N-linked oligosaccharides, an intermediate of mammalian hybrid- and complex-type oligosaccharides, while suppressing O-mannosylation. First, a yeast strain that produces a glycoprotein with Man5GlcNAc2 was isolated by introducing msdS encoding α-1,2-mannosidase into a strain synthesizing Man8GlcNAc2 N-linked oligosaccharides. Next, to suppress O-mannosylation, an O-mannosyltransferase-deficient strain was generated by disrupting PMT1 and PMT2 Although the relative amount of O-linked oligosaccharides in the disruptant was reduced to approximately 40% of that in wild type cells, this strain exhibited growth defects and decreased protein productivity. To overcome the growth defects, we applied a mutagenesis technique that is based on the disparity theory of evolution. Finally, to improve protein productivity of the growth-recovered strain, vacuolar proteases PEP4 and PRB1 were further disrupted. Thus, by combining genetic engineering and disparity mutagenesis, we generated an Saccharomyces cerevisiae strain whose N- and O-linked oligosaccharide synthetic pathways were engineered to effectively produce the heterologous protein.
Collapse
Affiliation(s)
- Hiroko Abe
- Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 2217-14 Hayashi, Takamatsu, Kagawa 761-0395, Japan
| | - Kazuya Tomimoto
- Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 2217-14 Hayashi, Takamatsu, Kagawa 761-0395, Japan
| | - Yasuko Fujita
- Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 2217-14 Hayashi, Takamatsu, Kagawa 761-0395, Japan
| | - Tomoko Iwaki
- Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 2217-14 Hayashi, Takamatsu, Kagawa 761-0395, Japan
| | - Yasunori Chiba
- Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan
| | - Ken-Ichi Nakayama
- Research Institute for Sustainable Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), 3-11-32 Kagamiyama, Higashi-Hiroshima, Hiroshima 739-0046, Japan
| | - Yoshihiro Nakajima
- Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 2217-14 Hayashi, Takamatsu, Kagawa 761-0395, Japan
| |
Collapse
|
8
|
Nagy G, Peng T, Pohl NLB. General Label-Free Mass Spectrometry-Based Assay To Identify Glycosidase Substrate Competence. Anal Chem 2016; 88:7183-90. [DOI: 10.1021/acs.analchem.6b01360] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Gabe Nagy
- Department of Chemistry, Indiana University, Bloomington, Indiana 47405, United States
| | - Tianyuan Peng
- Department of Chemistry, Indiana University, Bloomington, Indiana 47405, United States
| | - Nicola L. B. Pohl
- Department of Chemistry, Indiana University, Bloomington, Indiana 47405, United States
| |
Collapse
|
9
|
Dai M, Yu C, Fang T, Fu L, Wang J, Zhang J, Ren J, Xu J, Zhang X, Chen W. Identification and Functional Characterization of Glycosylation of Recombinant Human Platelet-Derived Growth Factor-BB in Pichia pastoris. PLoS One 2015; 10:e0145419. [PMID: 26701617 PMCID: PMC4689512 DOI: 10.1371/journal.pone.0145419] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2015] [Accepted: 12/03/2015] [Indexed: 01/02/2023] Open
Abstract
Yeast Pichia pastoris is a widely used system for heterologous protein expression. However, post-translational modifications, especially glycosylation, usually impede pharmaceutical application of recombinant proteins because of unexpected alterations in protein structure and function. The aim of this study was to identify glycosylation sites on recombinant human platelet-derived growth factor-BB (rhPDGF-BB) secreted by P. pastoris, and investigate possible effects of O-linked glycans on PDGF-BB functional activity. PDGF-BB secreted by P. pastoris is very heterogeneous and contains multiple isoforms. We demonstrated that PDGF-BB was O-glycosylated during the secretion process and detected putative O-glycosylation sites using glycosylation staining and immunoblotting. By site-directed mutagenesis and high-resolution LC/MS analysis, we, for the first time, identified two threonine residues at the C-terminus as the major O-glycosylation sites on rhPDGF-BB produced in P. pastoris. Although O-glycosylation resulted in heterogeneous protein expression, the removal of glycosylation sites did not affect rhPDGF-BB mitogenic activity. In addition, the unglycosylated PDGF-BBΔGly mutant exhibited the immunogenicity comparable to that of the wild-type form. Furthermore, antiserum against PDGF-BBΔGly also recognized glycosylated PDGF-BB, indicating that protein immunogenicity was unaltered by glycosylation. These findings elucidate the effect of glycosylation on PDGF-BB structure and biological activity, and can potentially contribute to the design and production of homogeneously expressed unglycosylated or human-type glycosylated PDGF-BB in P. pastoris for pharmaceutical applications.
Collapse
Affiliation(s)
- Mengmeng Dai
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China
- Clinical Laboratory, The 148th Hospital of PLA, Zibo, China
| | - Changming Yu
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Ting Fang
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Ling Fu
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Jing Wang
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Jun Zhang
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Jun Ren
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Junjie Xu
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Xiaopeng Zhang
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China
- * E-mail: (WC); (XZ)
| | - Wei Chen
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China
- * E-mail: (WC); (XZ)
| |
Collapse
|
10
|
Laukens B, Visscher CD, Callewaert N. Engineering yeast for producing human glycoproteins: where are we now? Future Microbiol 2015; 10:21-34. [DOI: 10.2217/fmb.14.104] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
ABSTRACT Yeast has advanced as an alternative for mammalian cell culture for the production of recombinant therapeutic glycoproteins. Engineered yeast strains not only allow to mimic the human N-glycosylation pathway but also specific types of human O-glycosylation. This is of great value for therapeutic protein production and indispensable to determine the structure-function relationships of glycans on recombinant proteins. However, as the technology matures, some limitations have come up that may hamper biomedical applications and must be considered to exploit the full potential of the unprecedented glycan homogeneity obtained on relevant biopharmaceuticals. In this special report, we focus on the recent developments in N- and O-glycosylation engineering in yeasts of industrial importance, to produce recombinant therapeutics with customized glycans.
Collapse
Affiliation(s)
- Bram Laukens
- Unit for Medical Biotechnology, Inflammation Research Centre (IRC), VIB-UGent, Technologiepark 927, B-9052 Ghent-Zwijnaarde, Belgium
- Department of Biochemistry & Microbiology, Laboratory for Protein Biochemistry & Biomolecular Engineering, Ghent University, K.L.-Ledeganckstraat 35, B-9000 Ghent, Belgium
| | - Charlotte De Visscher
- Unit for Medical Biotechnology, Inflammation Research Centre (IRC), VIB-UGent, Technologiepark 927, B-9052 Ghent-Zwijnaarde, Belgium
- Department of Biochemistry & Microbiology, Laboratory for Protein Biochemistry & Biomolecular Engineering, Ghent University, K.L.-Ledeganckstraat 35, B-9000 Ghent, Belgium
| | - Nico Callewaert
- Unit for Medical Biotechnology, Inflammation Research Centre (IRC), VIB-UGent, Technologiepark 927, B-9052 Ghent-Zwijnaarde, Belgium
- Department of Biochemistry & Microbiology, Laboratory for Protein Biochemistry & Biomolecular Engineering, Ghent University, K.L.-Ledeganckstraat 35, B-9000 Ghent, Belgium
- Department of Medical Protein Research, VIB-UGent, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium
| |
Collapse
|
11
|
Abstract
While yeast are lower eukaryotic organisms, they share many common features and biological processes with higher eukaryotes. As such, yeasts have been used as model organisms to facilitate our understanding of such features and processes. To this end, a large number of powerful genetic tools have been developed to investigate and manipulate these organisms. Going hand-in-hand with these genetic tools is the ability to efficiently scale up the fermentation of these organisms, thus making them attractive hosts for the production of recombinant proteins. A key feature of producing recombinant proteins in yeast is that these proteins can be readily secreted into the culture supernatant, simplifying any downstream processing. A consequence of this secretion is that the proteins typically pass through the secretory pathway, during which they may be exposed to various posttranslational modifications. The addition of glycans is one such modification. Unfortunately, while certain aspects of glycosylation are shared between lower and higher eukaryotes, significant differences exist. Over the last two decades much research has focused on engineering the glycosylation pathways of yeast to more closely resemble those of higher eukaryotes, particularly those of humans for the production of therapeutic proteins. In the current review we shall highlight some of the key achievements in yeast glyco-engineering which have led to humanization of both the N- and O-linked glycosylation pathways.
Collapse
|
12
|
Hopkins D, Gomathinayagam S, Hamilton SR. A practical approach for O-linked mannose removal: the use of recombinant lysosomal mannosidase. Appl Microbiol Biotechnol 2014; 99:3913-27. [PMID: 25381909 DOI: 10.1007/s00253-014-6189-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Revised: 10/22/2014] [Accepted: 10/23/2014] [Indexed: 11/30/2022]
Abstract
The methylotrophic yeast Pichia pastoris is an attractive expression system due to its ability to secrete large amounts of recombinant protein, with the potential for glycosylation. Advances in glycoengineering of P. pastoris have successfully demonstrated the humanization of both the N- and O-linked glycosylation pathways in this organism. However, in certain cases, the presence of O-linked glycans on a therapeutic protein may not be desirable. Recently, we have reported the in vitro utility of jack bean α-1,2/3/6-mannosidase to remove O-linked mannose from intact undenatured glycoproteins produced in glycoengineered P. pastoris. However, one caveat of this strategy is that jack bean mannosidase has yet to be cloned and as such is only available as crude cellular extracts. This raises several concerns for using this reagent to treat large preparations of therapeutic proteins generated in P. pastoris. Therefore, we postulated that lysosomal mannosidases which have been cloned and demonstrated to have similar activities to jack bean mannosidase on N-linked glycans would also process O-linked glycans in a similar fashion. To this end, we screened a panel of recombinant lysosomal mannosidases from different organisms and identified several which cannot only reduce extended O-linked mannose chains but which can also hydrolyze the Man-α-O-Ser/Thr glycosidic bond on intact glycoproteins. As such, not only do we show for the first time the utility of lysosomal mannosidase for O-linked mannose processing, but since this is a recombinant enzyme, it has several benefits over the use of crude jack bean mannosidase extracts.
Collapse
Affiliation(s)
- Daniel Hopkins
- GlycoFi, Inc. (a wholly owned subsidiary of Merck & Co., Inc.), Biologics Discovery, Merck Research Laboratories, 16 Cavendish Court, Lebanon, NH, 03766, USA
| | | | | |
Collapse
|